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Abstract
Aim: To evaluate the efficacy and tolerability of vardenafil, a phosphodiesterase type-5 (PDE-5) inhibitor, in men of
Asian ethnicity with erectile dysfunction (ED).  Methods: In this prospective, double-blind, multinational study, Asian
men were randomized to receive vardenafil (10 mg) or placebo (4:1 ratio) for 12 weeks.  The primary efficacy
variables were the International Index of Erectile Function erectile function domain (IIEF-EF), and Sexual Encounter
Profile (SEP) questions related to penetration and intercourse completion.  Significant mean improvements were
required in all three measures to show positive benefits of vardenafil treatment.  Secondary efficacy variables included
the Global Assessment Question (GAQ) on erection improvement. Results: Least-squares mean baseline IIEF-EF
domain scores (vardenafil 14.6, placebo 13.4) were consistent with moderate ED.  After 12 weeks, vardenafil treatment
was associated with significant increases from the baseline in IIEF-EF domain scores compared with the placebo (22.4
vs. 14.3; P < 0.001).  Vardenafil was associated with significant improvements from baseline in least squares (LS)
mean success rates for SEP-2 (vardenafil 82.2 vs. placebo 43.6; P < 0.001) and SEP-3 (vardenafil 66.1 vs. placebo
24.0; P < 0.001).  Positive GAQ responses were reported by 81.8% of vardenafil recipients vs. 24.3% of placebo
recipients.  Adverse events were reported by 25.4% of the vardenafil group, the majority mild and transient.  Conclusion:
Vardenafil (10 mg) is a highly effective and well-tolerated treatment for moderate ED in Asian men.  These results add
to the increasing amount of data demonstrating the safety and efficacy of vardenafil for the treatment of ED in a range
of patient populations. (Asian J Androl 2008 May; 10: 495–502)
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1    Introduction
Erectile dysfunction (ED) is a globally prevalent
condition, having detrimental effects on overall quality
of life, and providing a considerable source of emotional
stress for men and their partners [1–3].  The prevalence
of ED is expected to rise as populations age, with the
largest projected increases anticipated in Asia, Africa and
South America [4, 5].  According to age-adjusted pre-
dictions made using conservative projections for popu-
lation growth, the number of men worldwide with ED
could increase to 322 million by 2019 [5].
Phosphodiesterase type-5 (PDE-5) inhibitors are the
first-line therapeutic option in the treatment of ED.  The
phosphodiesterase (PDE) group of enzymes terminate
cyclic nucleotide signals, and PDE-5 is by far the most
active PDE involved in the termination of cyclic gua-
nosine monophosphate (cGMP) signalling in the corpus
cavernosum [6].  Inhibition of PDE-5 potentiates the bio-
logical activity of cGMP in the corpus cavernosum, in-
creasing smooth muscle relaxation and, therefore, improv-
ing erections, in the presence of a sexual stimulus [7].
The PDE-5 inhibitor vardenafil has been introduced
for the treatment of ED in various countries worldwide
since 2001 [8].  It has been effective and well-tolerated
in a broad range of patient populations, including those
with diabetes mellitus [9, 10], hypertension [11] and ED
following prostatectomy [12] or spinal cord injury [13].
The majority of previously reported clinical studies
of vardenafil have involved mostly Caucasian populations
[14–17].  Therefore, it is necessary to investigate the
safety and efficacy of vardenafil in other ethnic groups.
For example, Asian men might differ from Caucasian
men with regard to the polymorphic expression of key
enzymes responsible for drug metabolism [18, 19], and
in particular those that contribute to the metabolism of
vardenafil, such as CYP3A and CYP2C9 [18–20].
Moreover, there are differences between ethnic populations
with regard to perceptions of, and attitudes towards, ED
and cultural trends in medical practice [21, 22].  The study
evaluated the efficacy and tolerability of vardenafil in men
of Asian ethnicity with ED of broad-spectrum etiology.
2    Materials and methods
2.1  Study design
This prospective, randomized, double-blind, placebo-
controlled, fixed-dose, parallel-group study, conducted
between March 2003 and April 2004, assessed the safety
and efficacy of vardenafil (10 mg) for the treatment of
ED in Asian men.  Fourteen centres in six countries par-
ticipated in the study: Malaysia (4), Singapore (3), Thai-
land (3), the Philippines (2), Hong Kong, China (1) and
Indonesia (1).
The study protocol was approved by the appropriate
independent ethics committee at each site, and the study
was performed in accordance with the Good Clinical
Practice guidelines of the International Conference on
Harmonisation of Technical Requirements for the Regis-
tration of Pharmaceuticals for Human Use, and the prin-
ciples of the Declaration of Helsinki. All patients pro-
vided written informed consent.
2.2  Patients
Men aged ≥ 20 years with ED of > 6 months’ dura-
tion were enrolled.  Patients were required to have been in
a stable heterosexual relationship for > 6 months.  At least
50% of attempts to obtain, penetrate with, or maintain an
erection must have failed during at least four separate at-
tempts at intercourse during the 4-week baseline period.
The main exclusion criteria were: physiological or
psychological disorders that would significantly impair
erectile function; history of radical prostatectomy; re-
tinitis pigmentosa; and uncontrolled diabetes mellitus.  The
following medications were contraindicated: any drugs for
the treatment of ED including PDE-5 inhibitors, antico-
agulants (except antiplatelet agents), androgens or anti-
androgens, nitrates or nitric oxide donor medications; cy-
tochrome P450 3A4 inhibitors; and alpha blocking agents.
2.3  Study medication
After a 4-week baseline period, patients were ran-
domized (in a 4:1 ratio) to receive 12 weeks’ treatment
with vardenafil (10 mg) or placebo. The 10 mg vardenafil
dose was selected as this is the recommended starting
dose for the majority of patients.  Patients were advised
to dispense one tablet per instance of intended sexual
intercourse, and to take the study medication at least
30 min before sexual intercourse, with a maximum of
one dose daily.  The treatment phase was followed by a
7-day observation period.  Randomization codes were
computer-generated at Bayer Schering Pharma AG
(Leverkusen, Germany).
2.4  Efficacy variables
The primary efficacy variables used to assess erec-
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tile function were: (i) the International Index of Erectile
Function erectile function domain (IIEF-EF) score [23];
(ii) success rates for vaginal penetration, as assessed using
the Sexual Encounter Profile question 2 (SEP-2); and
(iii) success rates for maintaining penile rigidity for
completion of intercourse, as assessed using the Sexual
Encounter Profile question 3 (SEP-3).  For the efficacy
of vardenafil to be satisfactorily demonstrated, signifi-
cant improvements following vardenafil treatment vs.
placebo for all three of the primary variables, from
baseline to week 12 or last observation carried forward
(LOCF) were necessary.
Secondary efficacy variables included IIEF-EF do-
main scores, penetration success rates (SEP-2) and in-
tercourse completion rates (SEP-3) at 4, 8 and 12 weeks
or LOCF.  Responses to SEP questions on the achieve-
ment of erection (SEP-1), hardness of erection (SEP-4),
overall satisfaction with sexual experience (SEP-5), ejacu-
lation (SEP-6) and the Global Assessment Question
(GAQ) “Has the treatment you have been taking during
the last 4 weeks improved your erections?” were also
assessed at 4, 8 and 12 weeks or LOCF.
2.5  Safety assessments
Safety assessments included the reporting of adverse
events, laboratory tests (haematology, clinical chemistry,
urinalysis), monitoring of vital signs (heart rate and blood
pressure) and 12-lead electrocardiography.
2.6  Statistical methods
Sample size estimates were based on the assump-
tions of Student’s independent t-test. Assuming a stan-
dard deviation of 8.0 for the IIEF-EF domain score, a
total of 338 patients were necessary to show a clinically
meaningful difference of 5 points between vardenafil and
placebo, with an overall power of 90 %.
The safety population included all patients who had
received at least one dose of study medication and for
whom post-baseline safety data were provided.  All pa-
tients who received at least one dose of study medica-
tion and provided at least one measurement for all three
primary efficacy variables were included in the intent to
treat (ITT) population.  Analysis of IIEF-EF domain
scores, assessed at 4, 8 and 12 weeks, was performed
using an LOCF approach.  For diary questions, mean
success rates over the baseline and treatment periods
were averaged for all patients, and were reported as the
overall mean per patient success rate.  These efficacy
variables were assessed using analysis of covariance, with
baseline response as covariate (ANCOVA), to determine
the effects of vardenafil treatment.  Statistical analysis
of the secondary variable GAQ was performed using lo-
gistic regression
3    Results
3.1  Patients
A total of 413 men of Asian ethnicity were screened
for eligibility and 358 of these were randomized to treat-
ment (Figure 1).  Of these patients, 348 were eligible for
Figure 1. Patient disposition. ITT, intent-to-treat.
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Table 2. Efficacy scores in Asian men with erectile dysfunction (ED) after 12 weeks’ treatment with vardenafil (10 mg) or placebo (ITT
population). *P < 0.001 vs. placebo.  EF, erectile function; GAQ, Global Assessment Question; IIEF, International Index of Erectile
Function erectile function domain score; ITT, intent to treat; LOCF, last observation carried forward; LS, least square; SE, standard error;
SEP, Sexual Encounter Profile.
Placebo (n = 70) Vardenafil (10 mg, n = 264)
IIEF-EF domain at week 12 (LOCF)
LS mean baseline 13.4                                                       14.6
LS mean (SE) 14.30 (0.78)                                           22.40 (0.42)*
SEP-2 (penetration) until week 12 (LOCF)
LS mean baseline 49.0                                                        51.5
LS mean (SE) 43.6 (3.8)                                               82.2 (2.0)*
SEP-3 (completion) until week 12 (LOCF)
LS mean baseline 15.9                                                       19.4
LS mean (SE) 24.0 (4.7)                                               66.1 (2.5)*
GAQ (has treatment improved your erections?)
at week 12 (LOCF)
Patients responding “yes”, n (%) 17 (24.3)                                                216 (81.8)*
Table 1. Demographic characteristics and medical history of patients (safety population).Percentages are in parentheses. SD, standard
deviation.  ED, erectile dysfunction.
                           Placebo      Vardenafil (10 mg)
    Number of patients (%) 72 (100) 276 (100)
    Mean age (years, mean ± SD) 55.4 ± 11.0 54.4 ± 10.1
    Mean weight (kg, mean ± SD) 72.6 ± 15.3 71.6 ± 11.7
    Mean body mass index (kg/m2, mean ± SD) 26.3 ± 4.7 25.6 ± 3.8
    Past or present smoker (%) 34 (47) 92 (33)
    Medical history
        Hypertension (%) 28 (39) 98 (36)
        Diabetes mellitus (%) 27 (38) 84 (30)
    Aetiology of ED
        Organic (%) 44 (61) 149 (54)
        Psychogenic (%) 16 (22) 58 (21)
        Mixed (%) 12 (17) 69 (25)
    Prior sildenafil users (%) 46 (64) 178 (64)
inclusion in the safety population (276 vardenafil, 72
placebo).  The ITT population comprised 334 patients
(264 vardenafil, 70 placebo), who received study medi-
cation and provided data for all three major efficacy
variables.  Forty three patients (12.0%) prematurely dis-
continued study participation during the 12-week treat-
ment period.
Patients in the study population had a mean age of
54.6 years (range 23–78 years) and a mean weight of
72 kg.  There were no relevant differences in demo-
graphic characteristics or baseline clinical variables be-
tween the two treatment groups (Table 1).  The mean
baseline erectile function domain scores were 14.6 and
13.4 in the vardenafil and placebo groups, respectively,
consistent with a diagnosis of moderate ED (Table 2).  A
total of 224 patients had previously used sildenafil.  The
mean (SE) number of study medication doses taken per
week was 2.80 (1.38) in the vardenafil group and 2.40
(1.18) in the placebo group.
3.2  Efficacy
Following 12 weeks’ treatment, the LS mean
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Table 3.  Efficacy scores in Asian men with erectile dysfunction (ED) following 12 weeks’ treatment with vardenafil (10 mg) or placebo
(ITT population). *P < 0.001 vs placebo. LOCF, last observation carried forward; LS, least square; SEP, Sexual Encounter Profile; SE,
standard error.
             Placebo (n = 70)              Vardenafil  (10 mg, n = 264)
SEP-1 (achievement of erection) until week 12 (LOCF)
            LS mean baseline                                                                77.5                                           78.1
            LS mean (SE) 60.6 (3.5)                                  90.6 (1.9)*
          SEP-4 (hardness of erection) until week 12 (LOCF)
            LS mean baseline 9.2                                             7.1
            LS mean (SE)                                                                      12.6 (5.0)                                  61.4 (2.7)*
          SEP-5 (satisfaction with sexual experience) until week 12 (LOCF)
            LS mean baseline 10.7                                           9.9
            LS mean (SE) 15.2 (4.9)                                  62.8 (2.6)*
SEP-6 (ejaculation) until week 12 (LOCF)
            LS mean baseline 47.0                                           48.8
            LS mean (SE) 38.6 (4.1)                                  7.1 (2.2)*
Figure 2.  IIEF-EF domain scores at baseline and after 4, 8, and 12
weeks of treatment, and at LOCF with vardenafil (10 mg) or pla-
cebo (ITT population; *P < 0.001).  Dashed lines indicate baseline
values at each time-point.  ED, erectile dysfunction; IIEF-EF, In-
ternational Index of Erectile Function erectile function domain score;
ITT, intent to treat; LOCF, last observation carried forward; LS,
least saquares.
(standard error [SE]) IIEF-EF domain score in men re-
ceiving vardenafil (10 mg) was 22.40 (0.42); significantly
greater than the score of 14.30 (0.78) observed in men
receiving placebo (P < 0.001).  Vardenafil treatment was
also associated with significant improvements in the
other two primary efficacy variables after 12 weeks’
treatment (P < 0.001).  The LS mean (SE) SEP-2 per
patient success rates were 82.2 (2.0) and 43.6 (3.8) for
vardenafil and the placebo, respectively.  The LS mean
(SE) SEP-3 per patient success rates were 66.1 (2.5) in
the vardenafil group and 24.0 (4.7) in the placebo group
(Table 2).  For all three primary efficacy variables, clini-
cally significant therapeutic effects had occurred by the
time of the first assessment (4 weeks after the start of
treatment) with small additional improvements noted af-
ter this time-point (Figures 2–4).
Success rates for SEP-1, SEP-4, SEP-5 and SEP-6
questions at 12 weeks were all significantly improved
following vardenafil treatment compared with placebo
(P < 0.001; Table 3).  After 12 weeks, a significantly
greater percentage of patients responded positively to the
GAQ: 81.8% for vardenafil recipients vs. 24.3% for pla-
cebo recipients (P < 0.001) (Table 2).
3.3  Safety
In total, 70 (25.4%) patients in the vardenafil group
and 12 (16.7%) patients in the placebo group experi-
enced treatment-emergent adverse events.  As a result of
adverse events, six patients (2.2%) discontinued the
study, all of them in the study medication group.  The
most frequent treatment-emergent adverse events were
headache, flushing, nasal congestion and dizziness
(Table 4). Adverse events were slightly more frequent in
the vardenafil group than in the placebo group; however,
the majority were of mild intensity and were transient,
resolving spontaneously by the end of the observation
period.
Three patients in the vardenafil group reported seri-
ous adverse events, one of which was found to be drug-
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Figure 4.  Mean positive response rates to the Sexual Encounter
Profile (SEP)-3 question “Did your erection last long enough for
you to have successful intercourse?” at baseline and after 4, 8 and
12 weeks of treatment, and at LOCF with vardenafil (10 mg) or
placebo (ITT population; *P < 0.001). Dashed lines indicate
baseline values at each time-point.  ITT, intent to treat; LOCF, last
observation carried forward; LS, least squares.
Table 4. Treatment-emergent adverse events with an incidence ≥ 2%
in any treatment group (safety population).
Adverse event (n [%])                Placebo      Vardenafil (10 mg)
                                                    (n = 72)            (n = 276)
Any adverse event                     12 (16.7)           70 (25.4)
Gastrointestinal disorders            1 (1.4)               7 (2.5)
General disorders                         0                        6 (2.2)
Musculoskeletal disorders           0                      10 (3.6)
Headache                          4 (5.6)             20 (7.2)
Dizziness                          2 (2.8)               6 (2.2)
Nasal congestion                          1 (1.4)               9 (3.3)
Vascular disorders                        2 (2.8)               4 (1.4)
Flushing                                       0                      17 (6.2)
related.  In this reported case the patient suffered mode-
rate chest discomfort, which resolved following discon-
tinuation of treatment.
4    Discussion
ED has substantial negative effects on a patient’s
quality of life [1, 3] and a considerable emotional impact
on the lives of men and their partners, potentially depriv-
ing them of intimacy and diminishing their self-esteem
[2, 24].  It has been predicted that the prevalence of ED
in Asian countries will show greater increases in the fu-
ture than non-Asian countries [4, 5].  The Asian Men’s
Attitudes to Life Events and Sexuality (Asian MALES)
study confirms that ED is equally prevalent in Asian
countries.  The prevalence of ED varied by region, and
across all regions it was found to increase with age.  The
study also found that self-reported comorbid illnesses
were associated with the presence of ED, and that men
with ED exhibited significantly greater dissatisfaction with
all assessed aspects of quality of life.  Less than half of
men with self-reported ED in the Asian MALES Phase I
study had sought treatment for their problem [25].  The
findings of this study highlight the need to investigate the
efficacy and safety of PDE-5 inhibitors in Asian
populations.
In the present study, a broad population of men of
Asian ethnicity were recruited from Hong Kong (China),
Indonesia, the Philippines, Malaysia, Singapore and
Thailand.  ED was of moderate severity and mostly of
organic etiology.  Treatment with vardenafil (10 mg) im-
proved ED, as demonstrated by clinically relevant and
statistically significant improvements in the IIEF-EF do-
main score, and vaginal penetration success rates and
intercourse completion rates (assessed using the SEP-2
Figure 3.  Mean positive response rates to the Sexual Encounter
Profile (SEP)-2 question “Were you able to insert your penis in
your partner’s vagina?” at baseline and after 4, 8 and 12 weeks of
treatment, and at LOCF with vardenafil (10 mg) or placebo (ITT
population; *P < 0.001).  Dashed lines indicate baseline values at
each time-point.  ITT, intent to treat; LOCF, last observation car-
ried forward; LS, least squares.
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placebo.  These results add to the increasing amount of
data indicating that vardenafil is suitable for the treat-
ment of ED in a broad range of patient populations.
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